Antitumor combinations containing a VEGF inhibitor and 5FU or one of its derivatives
Details for Australian Patent Application No. 2005311191 (hide)
International Classifications
Event Publications
28 June 2007 PCT application entered the National Phase
PCT publication WO2006/059012 Priority application(s): WO2006/059012
8 December 2011 Application Accepted
Published as AU-B-2005311191
2 February 2012 Section 223 Application Allowed
Aventis Pharma S.A. The time in which to pay the response fees has been extended to 21 Jan 2012. Address for service in Australia - A J PARK Level 11 60 Marcus Clarke Street Canberra ACT 2601 2007
2 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This application lapsed under reg. 22.2E(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
5 April 2012 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2005311188-Novel pharmaceutical composition useful for vaccines
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional

- Editable Word format reports
- For IP Professionals
- Multiuser